Vanguard Group
OREX

Vanguard Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Vanguard Group’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-332,895
Closed -$429K – 4160
2017
Q4 		$429K Buy
332,895
+63,288
+23% +$103K ﹤0.01% 3783
2017
Q3 		$572K Buy
269,607
+8,793
+3% +$21.5K ﹤0.01% 3719
2017
Q2 		$756K Sell
260,814
-301,517
-54% -$904K ﹤0.01% 3637
2017
Q1 		$1.93M Buy
562,331
+263,474
+88% +$1.04M ﹤0.01% 3392
2016
Q4 		$520K Sell
298,857
-111,456
-27% -$262K ﹤0.01% 3727
2016
Q3 		$1.36M Sell
410,313
-20,741
-5% -$78.3K ﹤0.01% 3500
2016
Q2 		$1.85M Sell
431,054
-330,275
-43% -$1.49M ﹤0.01% 3407
2016
Q1 		$4.28M Buy
761,329
+155,681
+26% +$2.02M ﹤0.01% 3048
2015
Q4 		$10.4M Buy
605,648
+145,729
+32% +$3.47M ﹤0.01% 2614
2015
Q3 		$9.7M Buy
459,919
+7,642
+2% +$262K ﹤0.01% 2623
2015
Q2 		$22.4M Buy
452,277
+73,478
+19% +$4.39M ﹤0.01% 2303
2015
Q1 		$29.7M Buy
378,799
+12,198
+3% +$757K ﹤0.01% 2163
2014
Q4 		$22.2M Sell
366,601
-6,812
-2% -$342K ﹤0.01% 2195
2014
Q3 		$15.9M Buy
373,413
+74,186
+25% +$3.98M ﹤0.01% 2288
2014
Q2 		$18.5M Buy
299,227
+3,519
+1% +$205K ﹤0.01% 2244
2014
Q1 		$19.2M Buy
295,708
+18,237
+7% +$1.23M ﹤0.01% 2201
2013
Q4 		$15.6M Buy
277,471
+23,976
+9% +$1.35M ﹤0.01% 2261
2013
Q3 		$15.6M Buy
253,495
+30,985
+14% +$2.1M ﹤0.01% 2205
2013
Q2 		$13M Buy
+222,510
New +$13.7M ﹤0.01% 2219

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group's OREX Position: Q1 2018 in Review

Vanguard Group sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2018, closing a stake of 332,895 shares — an estimated $429K sold.

Vanguard Group first reported a position in OREX in Q2 2013 and held it in 19 quarters. The position peaked at $29.7M in Q1 2015. 27 funds tracked by Wall St. Rank hold OREX as of Q1 2018.

  • Vanguard Group reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Vanguard Group sold 332,895 Orexigen Therapeutics, Inc. shares in Q1 2018, an estimated $429K.
  • Vanguard Group first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
  • Vanguard Group's Orexigen Therapeutics, Inc. position peaked at $29.7M in Q1 2015.
  • 27 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2018.

Based on Vanguard Group's 13F filing for Q1 2018, filed 15 May 2018.